Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
The company is engaged in manufacturing of pharmaceuticals products.
Emcure Pharmaceuticals Limited, is an unlisted public company incorporated on 16 April, 1981. It is classified as a public limited company and is located in Pune, Maharashtra. It's authorized share capital is INR 250.00 cr and the total paid-up capital is INR 189.10 cr.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2023 numbers.
-8.27%
-44.82%
-64.18%
7.55%
5.97%
6.77%
-0.12
-9.35
-7.74
-17.4
-24.05
-0.01
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(70)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Axis Trustee Services Limited
No. of Loans: 9
Total Amount : 1,068.0 cr
Axis Bank Limited
No. of Loans: 13
Total Amount : 533.5 cr
Tata Capital Financial Services Limited
No. of Loans: 3
Total Amount : 170.0 cr
Bank of Baroda
No. of Loans: 1
Total Amount : 44.0 cr
HDFC Bank Limited
No. of Loans: 7
Total Amount : 2.6 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Whole-time Director | Mukund Keshao Gurjar
Shareholder
|
00026843 | 23 years |
| Whole-time Director | Sunil Rajanikant Mehta
Shareholder
|
00118469 | 12 years |
| Managing Director | Satish Ramanlal Mehta
Shareholder
|
00118691 | 44 years |
| CEO | Satish Ramanlal Mehta | <HIDDEN> | 4 years |
| Director | Berjis Minoo Desai
Shareholder
|
00153675 | 28 years |
| Director | Shailesh Kripalu Ayyangar | 00268076 | 4 years |
| Whole-time Director | Samit Satish Mehta
Shareholder
|
00332562 | 2 years |
| Director | Palamadai Sundararajan Jayakumar | 01173236 | 4 years |
| Director | Vidya Rajiv Yeravdekar | 02183179 | 4 years |
| Whole-time Director | Namita Vikas Thapar
Shareholder
|
05318899 | 10 years |
| Director | Samonnoi Sajani Banerjee | 06874206 | 7 years |
| Director | Vijay Keshav Gokhale | 09134089 | 4 years |
| Kmp | Chetan Rajendra Sharma | <HIDDEN> | 2 years |
| CFO | Tajuddin Sabir Shaikh | <HIDDEN> | 4 years |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| Emcure Pharma Peru S.A.C | Peru | - | - |
| Emcure Pharma Mexico S.A. DE C.V. | Mexico | - | - |
| Marcan Pharmaceuticals Inc | Canada | - | - |
| Emcure Pharmaceuticals Pty Ltd | Australia | - | - |
| Heritage Pharma Labs Inc. | United States | - | - |
| Tillomed Pharma GmbH | Germany | - | - |
| Tillomed Laboratories Ltd | United Kingdom | - | - |
| Laboratorios Tillomed Spain SLU | Spain | - | - |
| Tillomed Italia SRL | Italy | - | - |
| Emcure NZ Limited | New Zealand | - | - |
| GENNOVA BIOPHARMACEUTICALS LIMITED | Maharashtra | 2001 | ₹ 5.5 Cr |
| Heritage Pharmaceuticals Inc. | United States | - | - |
| Tillomed France SAS | France | - | - |
| Hacco Pharma Inc | United States | - | - |
| Tillomed Laboratories B.V. | Netherlands | - | - |
| AVET LIFESCIENCES PRIVATE LIMITED | Maharashtra | 2020 | ₹ 15.4 Cr |
| Emcure Pharma Chile SpA | Chile | - | - |
| Lazor Pharmaceuticals Ltd. | Kenya | - | - |
| ZUVENTUS HEALTHCARE LIMITED | Maharashtra | 2002 | ₹ 20.1 Cr |
| Emcure Nigeria Limited | Nigeria | - | - |
| Emcure Pharmaceuticals Mena FZ LLC | United Arab Emirates | - | - |
| Emcure Pharmaceuticals South Africa (Pty) Limited | South Africa | - | - |
| Emcure Brasil farmaceutica Ltda | Brazil | - | - |
| Heritage Pharma Holdings Inc. | United States | - | - |
| Emcure Pharma UK Ltd | United Kingdom | - | - |
| Emcure Pharma Philippines Inc. | Philippines | - | - |
| Tillomed d.o.o. | Croatia | - | - |
| Emcure Pharma Philippines Inc | Philippines | - | - |
The incorporation date of EMCURE PHARMACEUTICALS LIMITED is 16 April, 1981
The authorized share capital of EMCURE PHARMACEUTICALS LIMITED is INR ₹ 250.0 Cr.
The paid-up capital of EMCURE PHARMACEUTICALS LIMITED is INR ₹ 189.1 Cr.
The registered address of EMCURE PHARMACEUTICALS LIMITED is Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C. Infotech Park (Hinjawadi) Pune City Pune Maharashtra - 411057
The CIN number of EMCURE PHARMACEUTICALS LIMITED is U24231PN1981PLC024251.
Expand
Delete
Collapse
See
details
